NCT07536061
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 4 → 8 locations
- Notable Eligibility criteria expanded, about 9 words
- Study sites: 4 to 5
- Minor Study sites: 2 to 4v3
- Notable Recruitment opened
- Start date changed from estimate of May 5, 2026 to May 12, 2026
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants with a Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Adverse Event of Special Interest (AESI)
Timeframe: Baseline through Week 24
Secondary (3)
Plasma Concentration of SRP-1005
Urine Concentration of SRP-1005
Cerebrospinal Fluid Concentration of SRP-1005
Arms and interventions
Cohort 1: SRP-1005 Dose 1Experimental
Participants will receive SRP-1005 or placebo.
Cohort 2: SRP-1005 Dose 2Experimental
Participants will receive SRP-1005 or placebo.
Cohort 3: SRP-1005 Dose 3Experimental
Participants will receive SRP-1005 or placebo.
Cohort 4: SRP-1005 Dose 4Experimental
Participants will receive SRP-1005 or placebo.
Drugs: SRP-1005, Placebo
Sites
8 sites in 5 countries
United Kingdom 3, Australia 2, New Zealand 1, South Korea 1, Switzerland 1